NCT00064376已完成2 期
A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
详细描述
OBJECTIVES:
- Determine the clinical effects of paricalcitol in patients with myelodysplastic syndromes.
- Determine whether this drug can improve RBC, WBC, or platelet counts in these patients.
- Determine whether this drug can decrease the risk of development of leukemia without causing undue toxicity in these patients.
OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
H. Phillip Koeffler
Director, Medicine / Hematology/Oncology
Cedars-Sinai Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT04617067Cancer Trials Ireland15
已完成
4 期
Paricalcitol Effect on Anemia in CKDAnemiaChronic Kidney DiseaseNCT01768351Federico II University60
终止
4 期
Paricalcitol Improves Anemia of InflammationAnemiaNCT02876211Hospital Son Espases19
已完成
2 期
Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate CancerProstate CancerNCT00004043OHSU Knight Cancer Institute25
终止
1 期
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerPancreatic CancerNCT03520790Dana-Farber Cancer Institute36